Benitec Corp (BNTC) Long-Term Debt to Capital Ratio

Benitec Biopharma Inc. (BNTC) develops advanced gene therapy methods through gene silencing, with revenues based on investments and grants. Historical price action shows that the metric is 0.00. Business prospects are tied to BB-301 trials, the safety of the ddRNAi system, and liquidity reserves. Patent protection and FDA orphan drug exclusivity ensure the stability of its position.

This ratio compares liabilities with a maturity of over one year to total equity, determining the degree of financial leverage and the debt load on assets. Optimizing this balance is critical for Benitec Biopharma Inc., as stable financing supports costly biomaterial logistics, which is clearly reflected in the long-term debt-to-equity chart.